Tags Archive Navigation
icon
-
Media ReleaseNovartis hat im zweiten Quartal dank der Dynamik wichtiger Wachstums-marken eine starke Performance erzielt; Prognose für 2021 unverändert
-
Media ReleaseNovartis: forte performance au deuxième trimestre, soutenue par la dynamique des marques clés de croissance; prévisions pour l’exercice 2021 inchangées
-
Media ReleaseNovartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.
-
Media ReleaseNovartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA
-
Media ReleaseNovartis secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasis
-
Media ReleaseNovartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO
-
Media ReleaseNovartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutions
-
Media ReleaseWorld-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran)
-
Media ReleaseNovartis announces first FDA filing acceptance for anti-PD-1 antibody tislelizumab for people with esophageal cancer
-
Media ReleaseNovartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
-
Media ReleaseNovartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021
-
Media ReleaseNovartis announces collaboration on HARMONIA, a Phase III, head-to-head trial evaluating Kisqali® vs. Ibrance®* in patients with HR+/HER2- advanced breast cancer
Pagination
- ‹ Previous page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- …
- 31
- › Next page